Atropine

• Description:

  Atropine (Tropine tropate) is a competitive muscarinic acetylcholine receptor (mAChR) antagonist with IC50 values of 0.39 and 0.71 nM for Human mAChR M4 and Chicken mAChR M4, respectively. Atropine inhibits ACh-induced relaxations in human pulmonary veins. Atropine can be used for research of anti-myopia and bradycardia[1][2][3][4].

• Product Name Alternative:

  Tropine tropate; DL-Hyoscyamine

• UNSPSC:

  12352005

• Hazard Statement:

  H300, H330

• Target:

  Endogenous Metabolite; mAChR

• Type:

  Natural Products

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Atropine.html

• Purity:

  99.85

• Solubility:

  DMSO : ≥ 96.6 mg/mL|H2O : 2.9 mg/mL (ultrasonic; warming)

• Smiles:

  O=C(O[C@@H]1C[C@@H](N2C)CC[C@@H]2C1)C(CO)C3=CC=CC=C3

• Molecular Formula:

  C17H23NO3

• Molecular Weight:

  289.38

• Precautions:

  H300, H330

• References & Citations:

  [1]McBrien NA, et, al. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt. 2013 May;33 (3) :373-8.|[2]Morhardt JE. Heart rates, breathing rates and the effects of atropine and acetylcholine on white-footed mice (Peromyscus sp.) during daily torpor. Comp Biochem Physiol. 1970 Mar 15;33 (2) :441-57.|[3]Carr BJ, et, al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci. 2018 Jun 1;59 (7) :2778-2791.|[4]Walch L, et, al. Evidence for a M (1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol. 2000 May;130 (1) :73-8.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  MAChR4

• Citation 01:

  Can J Physiol Pharmacol. 2020 Oct;98 (10) :725-732.|Cardiovasc Drugs Ther. 2025 Apr 7.|Cell Metab. 2022 Dec 6;34 (12) :1999-2017.e10.|Cell Rep. 2022 Mar 8;38 (10) :110468.|Cell. 2025 Oct 24:S0092-8674 (25) 01129-8.|Eur J Pharmacol. 2024 Sep 3:176954.|Food Chem. 2022 Nov 30:395:133593.|Front Pharmacol. 2020 Jul 31;11:1038.|J Biosci. 2021:46:90.|J Ethnopharmacol. 2024 Jan 30;319 (Pt 2) :117192.|J Hazard Mater. 2024 Mar 5:465:133248.|J Hazard Mater. 2024 Sep 5:479:135690.|J Transl Med. 2025 Jan 23;23 (1) :112.|Research Square Preprint. 2022 Mar.|Research Square Print. 2023 Feb 7.|Research Square Print. December 16th, 2022.|Arch Oral Biol. 2023 Jan:145:105586.|Cell Discov. 2023 Feb 7;9 (1) :16.|Neuron. 2022 Nov 16;110 (22) :3774-3788.e7.

• CAS Number:

  [51-55-8]